Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

Recall Merck also tried to get an "improved

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
genisi Member Profile
 
Followed By 31
Posts 5,131
Boards Moderated 0
Alias Born 05/24/06
160x600 placeholder
Weidmann: German, Eurozone Growth Could Beat Forecasts - Report
"As things currently stand and if the oil price remains at current low levels, inflation will be even lower than forecast but growth will be higher," Mr. Weidmann tells Sunday newspaper Frankfurter Allgemeine Sonntagszeitung.
AirAsia Indonesia-to-Singapore Flight Loses Contact --Update
Petrobras Creates Special Committee Amid Corruption Allegations
China Investigating Senior Official at Anticompetition Watchdog -- Update
Antigraft Campaign Ripples Through China's Economy
U.S. Hot Stocks: Hot Stocks to Watch
Macy's Leads Ranking of Top 20 Finance Chiefs
Rockstar Consortium to Sell 4,000 Patents to RPX -- 3rd Update
European Stocks Rise As Oil Shares Gain; Afren Rallies
DirecTV, Disney in Distribution Pact
genisi   Wednesday, 04/27/11 03:49:51 AM
Re: biomaven0 post# 118902
Post # of 185216 
Recall Merck also tried to get an "improved niacin" by targeting the same receptor with MK-0354, which despite significant decreases in FFAs levels and absence of flushing failed to demonstrate effects on HDL/LDL-Cholesterol and TGs in phase II. Obviously, being a GPR109A receptor agonist isn't all.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist